生物製剤の世界市場調査レポート：産業分析、規模、シェア、成長、動向、2024年から2032年までの予測

生物製剤市場の世界需要は、2023年の5,530億9,000万米ドルから2032年には1兆288億7,000万米ドル近くの市場規模に達し、調査期間2024～2032年のCAGRは7.14%に達すると推定されます。

生物製剤は、タンパク質、核酸、炭水化物、細胞など、生体またはその構成成分に由来する医薬品です。化学合成された低分子の伝統的な医薬品とは異なり、生物製剤は組換えDNA技術、細胞培養、微生物発酵などのバイオテクノロジープロセスを用いて製造されます。生物製剤には、モノクローナル抗体、サイトカイン、ホルモン、酵素、ワクチン、遺伝子治療など様々な治療が含まれ、がん、自己免疫疾患、感染症、遺伝性疾患など複数の病状に対処するために使用されます。

市場力学

がん、自己免疫疾患、代謝性疾患のような慢性疾患の蔓延が加速していることが、標的を絞った個別化治療の選択肢を提供する生物学的療法に対する市場の需要を促進しています。生物学的製剤は、細胞、組織、タンパク質などの生体由来の高分子医薬品であり、従来の低分子医薬品と比較して、高い特異性、副作用の軽減、効能の向上などの利点があります。さらに、バイオテクノロジー、ゲノミクス、免疫学の進歩は、生物学的製剤の発見、開発、製造プロセスにおける技術革新を推進し、メーカーがアンメット・メディカル・ニーズに対する新規生物学的製剤を開発することを可能にしています。さらに、規制当局、医療提供者、患者による生物学的製剤の受容の拡大、償還範囲の拡大、市場アクセスの拡大が、腫瘍学、リウマチ学、皮膚科学、消化器病学などのさまざまな治療領域における生物学的製剤による治療の市場導入を加速しています。さらに、医療費の増加、中間所得層の拡大、医療サービスへのアクセスの改善などを背景に、新興経済圏における市場機会の拡大が、国の医療政策や国民皆保険構想の一環として生物学的製剤の需要を刺激しています。さらに、モノクローナル抗体、組換え蛋白質、細胞ベース療法などの新規生物学的製剤を発見・開発するための製薬会社、バイオテクノロジー新興企業、学術機関による研究開発投資の増加が、市場の革新と成長を促進しています。さらに、ゲノム配列決定、バイオマーカー同定、患者層別化の進展に後押しされた個別化医療と精密医療の動向の高まりが、個々の患者プロファイルと疾患特性に合わせた標的生物学的療法の市場機会を生み出しています。しかし、高い製造コスト、規制上のハードル、バイオシミラー製品との競合が市場成長の妨げになる可能性があります。

調査レポートは、ポーターのファイブフォースモデル、市場魅力度分析、バリューチェーン分析を取り上げています。これらのツールは、業界の構造を明確に把握し、世界レベルでの競合の魅力を評価するのに役立ちます。さらに、これらのツールは、生物製剤の世界市場における各セグメントを包括的に評価することもできます。生物製剤産業の成長と動向は、この調査に全体的なアプローチを記載しています。

市場セグメンテーション

生物製剤市場レポートの本セクションでは、国・地域レベルのセグメントに関する詳細なデータを提供することで、戦略担当者がそれぞれの製品またはサービスの対象層を特定し、今後のビジネス機会に役立てることができます。

製品別

• モノクローナル抗体
• 組み換えタンパク質
• ワクチン
• 細胞・遺伝子治療
• その他

用途別

• 腫瘍学
• 自己免疫・免疫疾患
• 血液疾患
• 感染症
• その他（心血管疾患など）

製造別

• 外部委託
• 自社製造

地域分析

本セクションでは、北米、欧州、アジア太平洋、ラテンアメリカ、中東・アフリカにおける生物製剤市場の現在と将来の需要を強調する地域展望を取り上げます。さらに、著名な全地域における各用途セグメントの需要・推定・予測にも焦点を当てています。

ご要望がございましたら、弊社までご連絡ください。当社の調査チームは、お客様のニーズに応じてカスタマイズしたレポートを提供することができます。

目次

第1章 序文

第2章 エグゼクティブサマリー

• 市場のハイライト
• 世界市場スナップショット

第3章 生物製剤-産業分析

• イントロダクション：市場力学
• 市場促進要因
• 市場抑制要因
• 機会
• 業界動向
• ポーターのファイブフォース分析
• 市場魅力度分析

第4章 バリューチェーン分析

• バリューチェーン分析
• 原材料分析
  • 原材料リスト
  • 原材料メーカー一覧
  • 主要原材料の価格動向
• 潜在的バイヤー一覧
• マーケティングチャネル
  • 直接マーケティング
  • 間接マーケティング
  • マーケティングチャネル発展動向

第5章 生物製剤の世界市場分析：製品別

• 製品別概要
• 実績データと予測データ
• 製品別分析
• モノクローナル抗体
• 組み換えタンパク質
• ワクチン
• 細胞・遺伝子治療
• その他

第6章 生物製剤の世界市場分析：用途別

• 用途別概要
• 実績データと予測データ
• 用途別分析
• がん領域
• 自己免疫・免疫疾患
• 血液疾患
• 感染症
• その他（心血管疾患など）

第7章 生物製剤の世界市場分析：製造別

• 製造別概要
• 実績データと予測データ
• 製造別分析
• 外部委託
• 自社製造

第8章 生物製剤の世界市場分析：地域別

• 地域別展望
• イントロダクション
• 北米売上分析
  • 概要、実績と予測
  • 北米：セグメント別
  • 北米：国別
  • 米国
  • カナダ
  • メキシコ
• 欧州売上分析
  • 概要、実績と予測
  • 欧州：セグメント別
  • 欧州：国別
  • 英国
  • フランス
  • ドイツ
  • イタリア
  • ロシア
  • その他の欧州
• アジア太平洋売上分析
  • 概要、実績と予測
  • アジア太平洋：セグメント別
  • アジア太平洋：国別
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア
  • 東南アジア
  • その他のアジア太平洋
• ラテンアメリカ売上分析
  • 概要、実績と予測
  • ラテンアメリカ：セグメント別
  • ラテンアメリカ：国別
  • ブラジル
  • アルゼンチン
  • ペルー
  • チリ
  • その他のラテンアメリカ
• 中東・アフリカ売上分析
  • 概要、実績と予測
  • 中東・アフリカ：セグメント別
  • 中東・アフリカ：国別
  • サウジアラビア
  • アラブ首長国連邦
  • イスラエル
  • 南アフリカ
  • その他の中東・アフリカ

第9章 生物製剤企業の競合情勢

• 生物製剤市場の競合
• 提携・協力・契約
• 合併・買収
• 新製品上市
• その他の開発

第10章 企業プロファイル

• 企業シェア分析
• 市場集中度
• AbbVie
• Amgen
• AstraZeneca
• Bristol-Myers Squibb Company
• Eli Lilly
• Gilead Sciences Inc.
• GlaxoSmithKline
• Johnson & Johnson Services Inc.
• Merck & Co. Inc.
• Novartis AG
• Pfizer Inc.
• F. Hoffmann-La Roche AG

LIST OF TABLES

• Market Snapshot
• Drivers : Impact Analysis
• Restraints : Impact Analysis
• List of Raw Material
• List of Raw Material Manufactures
• List of Potential Buyers
• Analysis by Product (USD MN)
• Monoclonal Antibodies Market Sales by Geography (USD MN)
• Recombinant Proteins Market Sales by Geography (USD MN)
• Vaccines Market Sales by Geography (USD MN)
• Cell & Gene Therapy Market Sales by Geography (USD MN)
• Others Market Sales by Geography (USD MN)
• Analysis Market by Application (USD MN)
• Oncology Market Sales by Geography (USD MN)
• Autoimmune & Immunological Disorders Market Sales by Geography (USD MN)
• Hematological Disorders Market Sales by Geography (USD MN)
• Infectious Diseases Market Sales by Geography (USD MN)
• Others (Cardiovascular Disorders, etc.) Market Sales by Geography (USD MN)
• Analysis by Manufacturing (USD MN)
• Outsourced Market Sales by Geography (USD MN)
• In-house Market Sales by Geography (USD MN)
• Global Biologics Market Sales by Geography (USD MN)
• North America Market Analysis (USD MN)
• United State Market Analysis (USD MN)
• Canada Market Analysis (USD MN)
• Mexico Market Analysis (USD MN)
• Europe Market Analysis (USD MN)
• Europe Market Estimate by Country (USD MN)
• United Kingdom Market Analysis (USD MN)
• France Market Analysis (USD MN)
• Germany Market Analysis (USD MN)
• Italy Market Analysis (USD MN)
• Russia Market Analysis (USD MN)
• Spain Market Analysis (USD MN)
• Rest of Europe Market Analysis (USD MN)
• Asia Pacific Market Analysis (USD MN)
• China Market Analysis (USD MN)
• Japan Market Analysis (USD MN)
• India Market Analysis (USD MN)
• South Korea Market Analysis (USD MN)
• Australia Market Analysis (USD MN)
• South East Asia Market Analysis (USD MN)
• Rest of Asia Pacific Market Analysis (USD MN)
• Latin America Market Analysis (USD MN)
• Brazil Market Analysis (USD MN)
• Argentina Market Analysis (USD MN)
• Peru Market Analysis (USD MN)
• Chile Market Analysis (USD MN)
• Rest of Latin America Market Analysis (USD MN)
• Middle East & Africa Market Analysis (USD MN)
• Saudi Arabia Market Analysis (USD MN)
• UAE Market Analysis (USD MN)
• Israel Market Analysis (USD MN)
• South Africa Market Analysis (USD MN)
• Rest of Middle East and Africa Market Analysis (USD MN)
• Partnership/Collaboration/Agreement
• Mergers And Acquisition

LIST OF FIGURES

• Research Scope of Biologics Report
• Market Research Process
• Market Research Methodology
• Global Biologics Market Size, by Region (USD MN)
• Porters Five Forces Analysis
• Market Attractiveness Analysis by Product
• Market Attractiveness Analysis by Application
• Market Attractiveness Analysis by Manufacturing
• Market Attractiveness Analysis by Region
• Value Chain Analysis
• Global Market Analysis by Product (USD MN)
• Monoclonal Antibodies Market Sales by Geography (USD MN)
• Recombinant Proteins Market Sales by Geography (USD MN)
• Vaccines Market Sales by Geography (USD MN)
• Cell & Gene Therapy Market Sales by Geography (USD MN)
• Others Market Sales by Geography (USD MN)
• Global Market Analysis by Application (USD MN)
• Oncology Market Sales by Geography (USD MN)
• Autoimmune & Immunological Disorders Market Sales by Geography (USD MN)
• Hematological Disorders Market Sales by Geography (USD MN)
• Infectious Diseases Market Sales by Geography (USD MN)
• Others (Cardiovascular Disorders, etc.) Market Sales by Geography (USD MN)
• Global Market Analysis by Manufacturing (USD MN)
• Outsourced Market Sales by Geography (USD MN)
• In-house Market Sales by Geography (USD MN)
• Global Market Sales (USD MN)
• North America Market Sales (USD MN)
• Europe Market Sales (USD MN)
• Asia Pacific Market Sales (USD MN)
• Latin America Market Sales (USD MN)
• Middle East & Africa Market Sales (USD MN)
• Recent Development in Industry
• Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.

The global demand for Biologics Market is presumed to reach the market size of nearly USD 1028.87 Billion by 2032 from USD 553.09 Billion in 2023 with a CAGR of 7.14% under the study period 2024 - 2032.

Biologics are pharmaceutical drugs derived from living organisms or their components, including proteins, nucleic acids, carbohydrates, or cells. Unlike small-molecule traditional medicines chemically synthesized, biologics are produced using biotechnological processes such as recombinant DNA technology, cell culture, or microbial fermentation. Biologics encompass various therapeutic agents, including monoclonal antibodies, cytokines, hormones, enzymes, vaccines, and gene therapies, used to address multiple medical conditions such as cancer, autoimmune diseases, infectious diseases, and genetic disorders.

MARKET DYNAMICS

The escalating prevalence of chronic diseases like cancer, autoimmune disorders, and metabolic diseases is driving market demand for biological therapies that offer targeted and personalized treatment options. Biologics are large molecule drugs derived from living organisms such as cells, tissues, and proteins, offering advantages such as higher specificity, reduced side effects, and improved efficacy compared to traditional small molecule drugs. Additionally, biotechnology, genomics, and immunology advancements propel innovation in biologic drug discovery, development, and manufacturing processes, enabling manufacturers to develop novel biologic therapies for unmet medical needs. Moreover, the growing acceptance of biologics by regulatory agencies, healthcare providers, and patients, coupled with increasing reimbursement coverage and market access, is accelerating the market adoption of biologic treatments in various therapeutic areas such as oncology, rheumatology, dermatology, and gastroenterology. Furthermore, the expanding market opportunities in emerging economies, driven by rising healthcare expenditures, expanding middle-class populations, and improving access to healthcare services, are stimulating demand for biologics as part of national healthcare policies and universal health coverage initiatives. Additionally, the increasing investments in research and development by pharmaceutical companies, biotechnology startups, and academic institutions to discover and develop novel biologic therapies, including monoclonal antibodies, recombinant proteins, and cell-based therapies, are driving market innovation and growth. Moreover, the growing trend of personalized medicine and precision healthcare, fueled by advances in genomic sequencing, biomarker identification, and patient stratification, is creating market opportunities for targeted biologic therapies tailored to individual patient profiles and disease characteristics. However, high production costs, regulatory hurdles, and competition from biosimilar products may hinder market growth.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of biologics. The growth and trends of biologics industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the biologics market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Product

• Monoclonal Antibodies
• Recombinant Proteins
• Vaccines
• Cell & Gene Therapy
• Others

By Application

• Oncology
• Autoimmune & Immunological Disorders
• Hematological Disorders
• Infectious Diseases
• Others (Cardiovascular Disorders, Etc.)

By Manufacturing

• Outsourced
• In-House

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Biologics market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Biologics market include AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly, Gilead Sciences, Inc., GlaxoSmithKline, Johnson & Johnson Services Inc., Merck & Co., Inc., Novartis AG, Pfizer Inc., F. Hoffmann-La Roche AG. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

• 1.1. Report Description
  • 1.1.1. Objective
  • 1.1.2. Target Audience
  • 1.1.3. Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1. Market Research Process
  • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3 . BIOLOGICS - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Product
  • 3.7.2 Market Attractiveness Analysis By Application
  • 3.7.3 Market Attractiveness Analysis By Manufacturing
  • 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1. List of Raw Materials
  • 4.2.2. Raw Material Manufactures List
  • 4.2.3. Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1. Direct Marketing
  • 4.4.2. Indirect Marketing
  • 4.4.3. Marketing Channel Development Trend

5 . GLOBAL BIOLOGICS MARKET ANALYSIS BY PRODUCT

• 5.1 Overview by Product
• 5.2 Historical and Forecast Data
• 5.3 Analysis by Product
• 5.4 Monoclonal Antibodies Historic and Forecast Sales by Regions
• 5.5 Recombinant Proteins Historic and Forecast Sales by Regions
• 5.6 Vaccines Historic and Forecast Sales by Regions
• 5.7 Cell & Gene Therapy Historic and Forecast Sales by Regions
• 5.8 Others Historic and Forecast Sales by Regions

6 . GLOBAL BIOLOGICS MARKET ANALYSIS BY APPLICATION

• 6.1 Overview by Application
• 6.2 Historical and Forecast Data
• 6.3 Analysis by Application
• 6.4 Oncology Historic and Forecast Sales by Regions
• 6.5 Autoimmune & Immunological Disorders Historic and Forecast Sales by Regions
• 6.6 Hematological Disorders Historic and Forecast Sales by Regions
• 6.7 Infectious Diseases Historic and Forecast Sales by Regions
• 6.8 Others (Cardiovascular Disorders, etc.) Historic and Forecast Sales by Regions

7 . GLOBAL BIOLOGICS MARKET ANALYSIS BY MANUFACTURING

• 7.1 Overview by Manufacturing
• 7.2 Historical and Forecast Data
• 7.3 Analysis by Manufacturing
• 7.4 Outsourced Historic and Forecast Sales by Regions
• 7.5 In-house Historic and Forecast Sales by Regions

8 . GLOBAL BIOLOGICS MARKET ANALYSIS BY GEOGRAPHY

• 8.1. Regional Outlook
• 8.2. Introduction
• 8.3. North America Sales Analysis
  • 8.3.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.3.2. North America By Segment Sales Analysis
  • 8.3.3. North America By Country Sales Analysis
  • 8.3.4. United State Sales Analysis
  • 8.3.5. Canada Sales Analysis
  • 8.3.6. Mexico Sales Analysis
• 8.4. Europe Sales Analysis
  • 8.4.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.4.2. Europe by Segment Sales Analysis
  • 8.4.3. Europe by Country Sales Analysis
  • 8.4.4. United Kingdom Sales Analysis
  • 8.4.5. France Sales Analysis
  • 8.4.6. Germany Sales Analysis
  • 8.4.7. Italy Sales Analysis
  • 8.4.8. Russia Sales Analysis
  • 8.4.9. Rest Of Europe Sales Analysis
• 8.5. Asia Pacific Sales Analysis
  • 8.5.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.5.2. Asia Pacific by Segment Sales Analysis
  • 8.5.3. Asia Pacific by Country Sales Analysis
  • 8.5.4. China Sales Analysis
  • 8.5.5. India Sales Analysis
  • 8.5.6. Japan Sales Analysis
  • 8.5.7. South Korea Sales Analysis
  • 8.5.8. Australia Sales Analysis
  • 8.5.9. South East Asia Sales Analysis
  • 8.5.10. Rest Of Asia Pacific Sales Analysis
• 8.6. Latin America Sales Analysis
  • 8.6.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.6.2. Latin America by Segment Sales Analysis
  • 8.6.3. Latin America by Country Sales Analysis
  • 8.6.4. Brazil Sales Analysis
  • 8.6.5. Argentina Sales Analysis
  • 8.6.6. Peru Sales Analysis
  • 8.6.7. Chile Sales Analysis
  • 8.6.8. Rest of Latin America Sales Analysis
• 8.7. Middle East & Africa Sales Analysis
  • 8.7.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.7.2. Middle East & Africa by Segment Sales Analysis
  • 8.7.3. Middle East & Africa by Country Sales Analysis
  • 8.7.4. Saudi Arabia Sales Analysis
  • 8.7.5. UAE Sales Analysis
  • 8.7.6. Israel Sales Analysis
  • 8.7.7. South Africa Sales Analysis
  • 8.7.8. Rest Of Middle East And Africa Sales Analysis

9 . COMPETITIVE LANDSCAPE OF THE BIOLOGICS COMPANIES

• 9.1. Biologics Market Competition
• 9.2. Partnership/Collaboration/Agreement
• 9.3. Merger And Acquisitions
• 9.4. New Product Launch
• 9.5. Other Developments

10 . COMPANY PROFILES OF BIOLOGICS INDUSTRY

• 10.1. Company Share Analysis
• 10.2. Market Concentration Rate
• 10.3. AbbVie
  • 10.3.1. Company Overview
  • 10.3.2. Company Revenue
  • 10.3.3. Products
  • 10.3.4. Recent Developments
• 10.4. Amgen
  • 10.4.1. Company Overview
  • 10.4.2. Company Revenue
  • 10.4.3. Products
  • 10.4.4. Recent Developments
• 10.5. AstraZeneca
  • 10.5.1. Company Overview
  • 10.5.2. Company Revenue
  • 10.5.3. Products
  • 10.5.4. Recent Developments
• 10.6. Bristol-Myers Squibb Company
  • 10.6.1. Company Overview
  • 10.6.2. Company Revenue
  • 10.6.3. Products
  • 10.6.4. Recent Developments
• 10.7. Eli Lilly
  • 10.7.1. Company Overview
  • 10.7.2. Company Revenue
  • 10.7.3. Products
  • 10.7.4. Recent Developments
• 10.8. Gilead Sciences Inc.
  • 10.8.1. Company Overview
  • 10.8.2. Company Revenue
  • 10.8.3. Products
  • 10.8.4. Recent Developments
• 10.9. GlaxoSmithKline
  • 10.9.1. Company Overview
  • 10.9.2. Company Revenue
  • 10.9.3. Products
  • 10.9.4. Recent Developments
• 10.10. Johnson & Johnson Services Inc.
  • 10.10.1. Company Overview
  • 10.10.2. Company Revenue
  • 10.10.3. Products
  • 10.10.4. Recent Developments
• 10.11. Merck & Co. Inc.
  • 10.11.1. Company Overview
  • 10.11.2. Company Revenue
  • 10.11.3. Products
  • 10.11.4. Recent Developments
• 10.12. Novartis AG
  • 10.12.1. Company Overview
  • 10.12.2. Company Revenue
  • 10.12.3. Products
  • 10.12.4. Recent Developments
• 10.13. Pfizer Inc.
  • 10.13.1. Company Overview
  • 10.13.2. Company Revenue
  • 10.13.3. Products
  • 10.13.4. Recent Developments
• 10.14. F. Hoffmann-La Roche AG
  • 10.14.1. Company Overview
  • 10.14.2. Company Revenue
  • 10.14.3. Products
  • 10.14.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies